@lymphomahub : CONGRESS | #SOHO25024 William Wierda, @MDAndersonNews, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are • TwiDoom

Lymphoma Hub

@lymphomahub

+ Follow

A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) linktr.ee/Lymphoma #lymsm

ID: 1582593798

linkhttp://www.lymphomahub.com calendar_today10-07-2013 08:56:22

10,10K Tweet

9,9K Followers

2,2K Following

Lymphoma Hub

@lymphomahub

15 days ago

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are

CONGRESS | #SOHO2024
William Wierda, <a href="/MDAndersonNews/">MD Anderson Cancer Center</a>, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are

thumb_up_off_alt14

chat_bubble_outline0

repeat7

shareShare